Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Erste Zwischenergebnisse der PERFORM-Studie zur Bewertung der endokrin-basierten Palbociclib-Erstlinientherapie für Patient:innen mit HR+/ HER2-fortgeschrittenem Brustkrebs in der Real World.

Fietz T., Wilke J., Deryal M., Gabrysiak T., Schöttker B., Jacobasch L., Petersen V., Weigel M., Wrobel D., Glastetter E., Berger L., Frank M., Woerner S.M., Adams A., Wöckel A., Lux M.P., 2022.

Oncol Res Treat 2022;45(suppl 2):108

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
PERFORM
2022
Charakteristika von Patienten mit lokal fortgeschrittenem oder metastasiertem Pankreaskarzinom und mehr als einem Jahr Überleben ab Beginn der Zweitlinientherapie – Daten aus dem klinischen Tumorregister Pankreaskarzinom (TPK).

Potthoff K., Hegewisch-Becker S., von der Heyde E., Nusch A., Binninger A., Wetzel N., Jänicke M., Reiser M., Wolf T., Marschner N., 2022.

Oncol Res Treat 2022;45(suppl 2):258

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TPK
2022
Behandlungssequenzen bei Patienten mit metastasiertem Adenokarzinom des Magens und des ösophago-gastralen Übergangs: Ergebnisse aus der deutschen Registerplattform SAPHIR.

Dechow T., Lorenzen S., Potthoff K., von der Heyde E., Dörfel S., Binninger A., Siebenbach H.U., Jänicke M., Zahn M.-O., Nusch A.,
Schulz H. Reinacher-Schick A., Lordick F., 2022.

Oncol Res Treat 2022;45(suppl 2):166

Indikation: Esophageal Cancer, Gastric Cancer, Magenkarzinom, Speiseröhrenkrebs / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
SAPHIR
2022
Current second-line treatment of patients with multiple myeloma – First outcome data of routine care treatment of patients with multiple myeloma in Germany – results from the MYRIAM registry.

Dechow, T., Einsele, H., Schweigert, M., Nusch, A., Jacobasch, L., Spohn, C., Kiewe, P., Gaska, T., Mahlmann, S., Strumberg, D., Jänicke, M., Potthoff, K., Medinger, T., Knauf, W., Engelhardt, M., 2022.

Oncol Res Treat 2022;45(suppl 2):11–346

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
MYRIAM
2022
Systemic treatment of advanced hepatocellular carcinoma in Germany – First results from the prospective national intersectoral cohort study JADE.

Schröder, J., Berg, T., Freiberg-Richter, J., Schlenska-Lange, A., von der Heyde, E., Schuler, M.K., Uhlig, J., Weinberg, F., Potthoff, K., Jänicke, M., Hofmann, W.P., Pereira, P., Thimme, R., Galle, P.R., 2022.

Oncol Res Treat 2022;45(suppl 2):11–346

Download

Indikation: Leberkrebs, Liver Cancer / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
JADE
2022
First Real-World outcome data of SCLC in Germany – Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)

M. Sebastian, M. Reck, R. Fischer, D. Christoph, C. Bernhardt, E. von der Heyde, A. Nusch, P. Ludwig, A. Hipper, J. Hanselmann, T. Medinger, A. Binninger, M. Jänicke, P. Christopoulos, C. Elender, A. Bethge, B. Seese, T. Gauler, C. F. Waller, 2022.

Oncol Res Treat 2022;45(suppl 2):11–346

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2022
Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315).

M Sebastian, F Griesinger, E von der Heyde, S Dörfel, J Wiegand, C Schiefer, C Losem, M Jänicke, A Fleitz, S Zacharias, A Hipper, C Dietel, A Bleckmann, R Benkelmann, M Boesche, C Grah, A Müller, WEE Eberhardt, M Thomas, 2022.

Oncol Res Treat 2022;45(suppl 2):11–346

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2022
First Real-World outcome data of SCLC in Germany – Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)

M. Sebastian, M. Reck, R. Fischer, D. Christoph, C. Bernhardt, E. von der Heyde, A. Nusch, P. Ludwig, A. Hipper, J. Hanselmann, T. Medinger, A. Binninger, M. Jänicke, P. Christopoulos, C. Elender, A. Bethge, B. Seese, T. Gauler, C. F. Waller, 2022.

Ann. Onc. 2022, Volume 33, Supplement 7, Pages S545-S1382.

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
CRISP
2022
Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315).

M Sebastian, F Griesinger, E von der Heyde, S Dörfel, J Wiegand, C Schiefer, C Losem, M Jänicke, A Fleitz, S Zacharias, A Hipper, C Dietel, A Bleckmann, R Benkelmann, M Boesche, C Grah, A Müller, WEE Eberhardt, M Thomas, 2022.

Ann. Onc. 2022, Volume 33, Supplement 7, Pages S545-S1382.

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal:
CRISP
2022
Routine care of early breast cancer (stage I-III) in germany. Data of the prospective, intersectoral research platform OPAL.

Welt A, Zahn MO, Wöckel A, Stickeler E, Thoma M, Nusch A, u. a. 2022

Annals of Oncology. 2022;33(187P):S622.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
OPAL
2022